We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended December 2023, Pfizer (PFE - Free Report) reported revenue of $14.25 billion, down 41.3% over the same period last year. EPS came in at $0.10, compared to $1.14 in the year-ago quarter.
The reported revenue represents a surprise of -0.80% over the Zacks Consensus Estimate of $14.36 billion. With the consensus EPS estimate being -$0.19, the EPS surprise was +152.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Oncology- Ibrance; United States: $712 million versus $826.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -18.7% change.
Revenues- Oncology- Ibrance- Total International: $405 million versus the four-analyst average estimate of $383.27 million. The reported number represents a year-over-year change of +0.5%.
Revenues- Specialty Care- Inflectra- United States: $63 million versus the four-analyst average estimate of $57.63 million. The reported number represents a year-over-year change of +1.6%.
Revenues- Specialty Care- Inflectra- Total International: $54 million versus $65.95 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -20.6% change.
Revenues- Oncology- Inlyta- Worldwide: $263 million compared to the $256.07 million average estimate based on four analysts.
Revenues- Specialty Care- Vyndaqel family- Worldwide: $961 million compared to the $945.42 million average estimate based on four analysts. The reported number represents a change of +41.3% year over year.
Pfizer Biopharma- Total: $13.87 billion versus the four-analyst average estimate of $13.93 billion.
Revenues- Specialty Care- Xeljanz- Worldwide: $493 million versus $489.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide: $282 million versus the four-analyst average estimate of $251.43 million.
Revenues- Primary Care- Comirnaty direct sales and alliance revenues - Worldwide: $5.36 billion versus the four-analyst average estimate of $5.58 billion.
Revenues- Pfizer CentreOne- Worldwide: $363 million compared to the $331.31 million average estimate based on four analysts. The reported number represents a change of -1.4% year over year.
Revenue- Specialty Care- Worldwide: $3.95 billion versus $3.85 billion estimated by four analysts on average.
Shares of Pfizer have returned -4.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended December 2023, Pfizer (PFE - Free Report) reported revenue of $14.25 billion, down 41.3% over the same period last year. EPS came in at $0.10, compared to $1.14 in the year-ago quarter.
The reported revenue represents a surprise of -0.80% over the Zacks Consensus Estimate of $14.36 billion. With the consensus EPS estimate being -$0.19, the EPS surprise was +152.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Oncology- Ibrance; United States: $712 million versus $826.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -18.7% change.
- Revenues- Oncology- Ibrance- Total International: $405 million versus the four-analyst average estimate of $383.27 million. The reported number represents a year-over-year change of +0.5%.
- Revenues- Specialty Care- Inflectra- United States: $63 million versus the four-analyst average estimate of $57.63 million. The reported number represents a year-over-year change of +1.6%.
- Revenues- Specialty Care- Inflectra- Total International: $54 million versus $65.95 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -20.6% change.
- Revenues- Oncology- Inlyta- Worldwide: $263 million compared to the $256.07 million average estimate based on four analysts.
- Revenues- Specialty Care- Vyndaqel family- Worldwide: $961 million compared to the $945.42 million average estimate based on four analysts. The reported number represents a change of +41.3% year over year.
- Pfizer Biopharma- Total: $13.87 billion versus the four-analyst average estimate of $13.93 billion.
- Revenues- Specialty Care- Xeljanz- Worldwide: $493 million versus $489.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide: $282 million versus the four-analyst average estimate of $251.43 million.
- Revenues- Primary Care- Comirnaty direct sales and alliance revenues - Worldwide: $5.36 billion versus the four-analyst average estimate of $5.58 billion.
- Revenues- Pfizer CentreOne- Worldwide: $363 million compared to the $331.31 million average estimate based on four analysts. The reported number represents a change of -1.4% year over year.
- Revenue- Specialty Care- Worldwide: $3.95 billion versus $3.85 billion estimated by four analysts on average.
View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -4.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.